These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 19327619)

  • 1. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial.
    Dschietzig T; Teichman S; Unemori E; Wood S; Boehmer J; Richter C; Baumann G; Stangl K
    J Card Fail; 2009 Apr; 15(3):182-90. PubMed ID: 19327619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First clinical experience with intravenous recombinant human relaxin in compensated heart failure.
    Dschietzig T; Teichman S; Unemori E; Wood S; Boehmer J; Richter C; Baumann G; Stangl K
    Ann N Y Acad Sci; 2009 Apr; 1160():387-92. PubMed ID: 19416226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent outpatient nesiritide infusion reduces hospital admissions in patients with advanced heart failure.
    Schwarz ER; Najam S; Akel R; Sulimanjee N; Bionat S; Rosanio S
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):232-6. PubMed ID: 17875951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart.
    Forfia PR; Lee M; Tunin RS; Mahmud M; Champion HC; Kass DA
    J Am Coll Cardiol; 2007 Mar; 49(10):1079-88. PubMed ID: 17349888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of the RELAXin in acute heart failure study.
    Ponikowski P; Metra M; Teerlink JR; Unemori E; Felker GM; Voors AA; Filippatos G; Greenberg B; Teichman SL; Severin T; Mueller-Velten G; Cotter G; Davison BA
    Am Heart J; 2012 Feb; 163(2):149-55.e1. PubMed ID: 22305830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.
    Teerlink JR; Metra M; Felker GM; Ponikowski P; Voors AA; Weatherley BD; Marmor A; Katz A; Grzybowski J; Unemori E; Teichman SL; Cotter G
    Lancet; 2009 Apr; 373(9673):1429-39. PubMed ID: 19329178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of serial home infusions of nesiritide for advanced heart failure.
    Chung ES; Menon SG; Daly KA; Atkinson J; Peterson T; Robertson R; Ibanez K; Kereiakes DJ
    Am J Cardiol; 2006 May; 97(9):1370-3. PubMed ID: 16635613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
    Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR;
    J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of intravenous recombinant human brain natriuretic peptide in patients with decompensated acute heart failure: a multicenter, randomized, open label, controlled study].
    ; Hu DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Apr; 39(4):305-8. PubMed ID: 21624304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential renal protective benefits of intra-operative BNP infusion during cardiac transplantation.
    Zierer A; Voeller RK; Melby SJ; Kawa CB; Guthrie TJ; Baumgartner M; Pasque MK; Moon MR; Moazami N
    Transplant Proc; 2006 Dec; 38(10):3680-4. PubMed ID: 17175366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.
    Ghali JK; Smith WB; Torre-Amione G; Haynos W; Rayburn BK; Amato A; Zhang D; Cowart D; Valentini G; Carminati P; Gheorghiade M
    Am J Cardiol; 2007 Jan; 99(2A):47A-56A. PubMed ID: 17239705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
    Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
    Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic effect of recombinant human brain natriuretic peptide for treatment of decompensated heart failure: comparison with nitroglycerin].
    Xie CL; Meng SR; Wang W; Chen SM; Li P; Feng XG
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):839-42. PubMed ID: 18504215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil.
    Melenovsky V; Al-Hiti H; Kazdova L; Jabor A; Syrovatka P; Malek I; Kettner J; Kautzner J
    J Am Coll Cardiol; 2009 Aug; 54(7):595-600. PubMed ID: 19660688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure.
    Rademaker MT; Cameron VA; Charles CJ; Richards AM
    Circulation; 2005 Dec; 112(23):3624-32. PubMed ID: 16330704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of N-terminal pro-brain natriuretic peptide and cystatin C to estimate renal function in patients with and without heart failure.
    Linzbach S; Samigullin A; Yilmaz S; Tsioga M; Zeiher AM; Spyridopoulos I
    Am J Cardiol; 2009 Apr; 103(8):1128-33. PubMed ID: 19361601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
    Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M;
    Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis.
    Seibold JR; Clements PJ; Furst DE; Mayes MD; McCloskey DA; Moreland LW; White B; Wigley FM; Rocco S; Erikson M; Hannigan JF; Sanders ME; Amento EP
    J Rheumatol; 1998 Feb; 25(2):302-7. PubMed ID: 9489823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relaxin: a new approach for the treatment of acute congestive heart failure.
    Grossman J; Frishman WH
    Cardiol Rev; 2010; 18(6):305-12. PubMed ID: 20926940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.
    Manzano-Fernández S; Boronat-Garcia M; Albaladejo-Otón MD; Pastor P; Garrido IP; Pastor-Pérez FJ; Martínez-Hernández P; Valdés M; Pascual-Figal DA
    Am J Cardiol; 2009 Jun; 103(12):1753-9. PubMed ID: 19539088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.